- Home
- RAMP vs JANX Comparison
RAMP vs JANX Comparison
Compare RAMP & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RAMP
- JANX
- Stock Information
- Founded
- RAMP 2018
- JANX 2017
- Country
- RAMP United States
- JANX United States
- Employees
- RAMP N/A
- JANX N/A
- Industry
- RAMP EDP Services
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- RAMP Technology
- JANX Health Care
- Exchange
- RAMP Nasdaq
- JANX Nasdaq
- Market Cap
- RAMP 1.8B
- JANX 1.6B
- IPO Year
- RAMP 1987
- JANX 2021
- Fundamental
- Price
- RAMP $30.46
- JANX $23.60
- Analyst Decision
- RAMP Buy
- JANX Strong Buy
- Analyst Count
- RAMP 6
- JANX 7
- Target Price
- RAMP $40.67
- JANX $94.29
- AVG Volume (30 Days)
- RAMP 651.1K
- JANX 808.2K
- Earning Date
- RAMP 08-06-2025
- JANX 08-06-2025
- Dividend Yield
- RAMP N/A
- JANX N/A
- EPS Growth
- RAMP N/A
- JANX N/A
- EPS
- RAMP N/A
- JANX N/A
- Revenue
- RAMP $745,580,000.00
- JANX $9,336,000.00
- Revenue This Year
- RAMP $10.01
- JANX N/A
- Revenue Next Year
- RAMP $9.39
- JANX $1,470.82
- P/E Ratio
- RAMP N/A
- JANX N/A
- Revenue Growth
- RAMP 13.03
- JANX 28.12
- 52 Week Low
- RAMP $21.45
- JANX $22.48
- 52 Week High
- RAMP $36.08
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- RAMP 46.00
- JANX 41.60
- Support Level
- RAMP $29.80
- JANX $24.45
- Resistance Level
- RAMP $31.89
- JANX $27.28
- Average True Range (ATR)
- RAMP 0.69
- JANX 1.35
- MACD
- RAMP -0.48
- JANX -0.09
- Stochastic Oscillator
- RAMP 16.92
- JANX 22.20
About RAMP LiveRamp Holdings Inc.
LiveRamp Holdings Inc is a global technology company that helps companies build enduring brand and business value by collaborating responsibly with data. A groundbreaking leader in consumer privacy, data ethics and foundational identity, LiveRamp offers a connected customer view with clarity and context while protecting brand and consumer trust.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.